CEO Marc Gleeson (Azura)
October 22, 2020 08:05 AM EDT
Financing

Azu­ra Oph­thalmics gets a $20M boost for its R&D work on eye dis­eases

Nicole DeFeudis

Editor

Three years af­ter clos­ing a $16 mil­lion Se­ries B, the same group of in­vestors are back to give Azu­ra Oph­thalmics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Will CRISPR mat­ter?

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times